



**Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022  
Financial Results and Business Update on Thursday, May 5**

*- Live Conference Call and Webcast at 4:30 PM ET -*

Palo Alto, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update.

The live and replayed webcast of the call will be available through the company's website at [www.eigerbio.com](http://www.eigerbio.com). To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 2392544. The webcast will be archived and available for replay for at least 90 days after the event.

**About Eiger**

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.

For additional information about Eiger and its clinical programs, please visit [www.eigerbio.com](http://www.eigerbio.com).

SOURCE Eiger BioPharmaceuticals, Inc.

Investors:  
Sylvia Wheeler  
Wheelhouse Life Science Advisors  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)

Media:  
Sarah Mathieson  
SVP, Corporate Affairs  
[smathieson@eigerbio.com](mailto:smathieson@eigerbio.com)